Among chronic myeloid leukemia (CML) patients, higher imatinib exposures were associated with better overall survival (OS) and event-free survival (EFS), according to an analysis of data from the WORLD CML Registry presented during the 54th American Society of Hematology Annual Meeting and Exposition.
Ponatinib has substantial activity and is generally well tolerated in heavily pretreated patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation.
In patients with newly diagnosed chronic phase chronic myeloid leukemia treated with bosutinib, an early Bcr-Abl/Abl ratio of ≤10% was associated with higher rates of major molecular response and complete cytogenetic response, according to data presented at the 54th American Society of Hematology Annual Meeting and Exposition.
Once-daily ponatinib, a pan-BCR-ABL inhibitor, was “highly active” in heavily pretreated patients with Philadelphia chromosome-positive leukemias resistant to tyrosine kinase inhibitors.
Teva Pharmaceuticals announced that the FDA has approved Synribo (omacetaxine mepesuccinate) for Injection to treat adult patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).
ARIAD Pharmaceuticals announced that the FDA has accepted for filing the New Drug Application (NDA) of ponatinib for patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL); the FDA also has granted ARIAD’s request for Priority Review.
This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.
Ibrutinib (PCI-32765) is highly active and well tolerated in relapsed or refractory (R/R) and elderly treatment-naïve (TN) patients with chronic myeloid leukemia (CLL).
Ponatinib has substantial activity in treatment-refractory patients with acute lymphomblastic leukemia (ALL) or chronic myeloid leukemia (CML).
Long-term treatment with dasatinib is safe and efficacious in patients with imatinib-resistant, chronic phase chronic myeloid leukemia (CP-CML).
